Merck KGaA's pimicotinib met its primary endpoint in Phase 3 MANEUVER trial for tenosynovial giant cell tumors, showing 54% ...
Samsung Electronics Co. Ltd.-1.52% ₩387.54T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback